{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T18:47:36Z","timestamp":1778266056897,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,4]],"date-time":"2022-12-04T00:00:00Z","timestamp":1670112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,4]],"date-time":"2022-12-04T00:00:00Z","timestamp":1670112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008108","name":"Taipei Tzu Chi Hospital","doi-asserted-by":"crossref","award":["TCRD-TPE-109-53"],"award-info":[{"award-number":["TCRD-TPE-109-53"]}],"id":[{"id":"10.13039\/501100008108","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008108","name":"Taipei Tzu Chi Hospital","doi-asserted-by":"crossref","award":["TCRD-TPE-111-19"],"award-info":[{"award-number":["TCRD-TPE-111-19"]}],"id":[{"id":"10.13039\/501100008108","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005925","name":"Buddhist Tzu Chi Medical Foundation","doi-asserted-by":"crossref","award":["TCMF-A 109-05 (111)"],"award-info":[{"award-number":["TCMF-A 109-05 (111)"]}],"id":[{"id":"10.13039\/501100005925","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Heme oxygenase one (HO-1) is considered a poor prognostic factor for survival in patients with severe-to-critical coronavirus disease (COVID-19), but the clinical correlation between heme catabolism biomarkers and COVID-19-related sepsis is unknown. The etiopathogenetic hypothesis of HO-1 response during sepsis in patients with poor prognosis should be clarified. This study aimed to investigate sepsis development within 48\u00a0h following moderate-to-critical COVID-19 and examined heme\/HO-1 catabolism biomarkers associated with sepsis. We also studied the HO-1 and traditional prognostic factors for predicting survival in patients with COVID-19.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective observational study included patients unvaccinated for COVID-19 with moderate-to-critical COVID-19 (<jats:italic>n<\/jats:italic>\u2009=\u2009156) who had been admitted to Taipei Tzu Chi Hospital in 2021. All COVID-19 patients were diagnosed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcriptase polymerase chain reaction. For analysis of heme catabolism in SARS-CoV-2-induced sepsis, we excluded patients with co-infection and severe anemia. Heme catabolism biomarkers were compared between groups of patients with COVID-19 and sepsis (sepsis) and those with COVID-19 without sepsis (no sepsis), and a control group comprising 100 healthy individuals. All clinical and laboratory data were collected retrospectively and blood specimens were collected from Biobank. Multivariable logistic regression analysis was used to compare all variables between the sepsis and no-sepsis groups. Cox regression analysis was used to determine predictors of survival in patients with COVID-19.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There were 71 and 85 patients with and without sepsis, respectively. Heme and HO-1 levels differed significantly between the sepsis, no sepsis, and control groups. In multivariate analysis, confusion, blood urea nitrogen, respiration, blood pressure in patients aged\u2009&gt;\u200965\u00a0years (CURB-65) (adjusted odds ratio [aOR] 5.331, 95% confidence interval [CI] 2.587\u201310.987; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), albumin (aOR 0.139, 95% CI 0.003\u20130.636; <jats:italic>p<\/jats:italic>\u2009=\u20090.01), <jats:sc>d<\/jats:sc>-dimer (aOR 1.001, 95% CI 1.000\u20131.002; <jats:italic>p<\/jats:italic>\u2009=\u20090.032), and HO-1 (aOR 1.116, 95% CI 1.055\u20131.180; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) were significantly associated with 48-h sepsis episodes after adjusting for other confounding factors. HO-1 levels were also significantly associated with 48-h Sequential Organ Failure Assessment Score (SOFA) scores. However, HO-1 did not significantly increase the hazard of in-hospital mortality in moderate-to-critical COVID-19 by Cox regression analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>HO-1 levels increased with sepsis development within 48\u00a0h of admission for COVID-19 after adjusting for other risk factors, but no significant association was observed between HO-1 and COVID-19 mortality. We suppose that HO-1 may have protective effect in early sepsis, but further clinical multicenter prospective studies are needed.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40001-022-00915-5","type":"journal-article","created":{"date-parts":[[2022,12,4]],"date-time":"2022-12-04T10:02:42Z","timestamp":1670148162000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Association between heme oxygenase one and sepsis development in patients with moderate-to-critical COVID-19: a single-center, retrospective observational study"],"prefix":"10.1186","volume":"27","author":[{"given":"Hsin-Yi","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I-Shiang","family":"Tzeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuo-Wang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-Kuang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Feng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuo-Cheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsueh-Wen","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You-Chen","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Lin","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,4]]},"reference":[{"key":"915_CR1","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","volume":"323","author":"Z Wu","year":"2020","unstructured":"Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239\u201342.","journal-title":"JAMA"},{"key":"915_CR2","doi-asserted-by":"publisher","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","volume":"49","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49:e1063\u2013143.","journal-title":"Crit Care Med"},{"key":"915_CR3","doi-asserted-by":"publisher","first-page":"e219","DOI":"10.1097\/CCM.0000000000004899","volume":"49","author":"W Alhazzani","year":"2021","unstructured":"Alhazzani W, Evans L, Alshamsi F, Moller MH, Ostermann M, Prescott HC, et al. Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update. Crit Care Med. 2021;49:e219\u201334.","journal-title":"Crit Care Med"},{"key":"915_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1165\/rcmb.2006-0331TR","volume":"36","author":"LE Fredenburgh","year":"2007","unstructured":"Fredenburgh LE, Perrella MA, Mitsialis SA. The role of heme oxygenase-1 in pulmonary disease. Am J Respir Cell Mol Biol. 2007;36:158\u201365.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"915_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/CCM.0000000000004131","volume":"48","author":"G Lachmann","year":"2020","unstructured":"Lachmann G, Knaak C, Vorderwulbecke G, La Rosee P, Balzer F, Schenk T, et al. Hyperferritinemia in critically ill patients. Crit Care Med. 2020;48:459\u201365.","journal-title":"Crit Care Med"},{"key":"915_CR6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/cc11381","volume":"16","author":"N Nesseler","year":"2012","unstructured":"Nesseler N, Launey Y, Aninat C, Morel F, Malledant Y, Seguin P. Clinical review: the liver in sepsis. Crit Care. 2012;16:235.","journal-title":"Crit Care"},{"key":"915_CR7","doi-asserted-by":"publisher","first-page":"11198","DOI":"10.1038\/s41598-018-29558-5","volume":"8","author":"P Ekregbesi","year":"2018","unstructured":"Ekregbesi P, Shankar-Hari M, Bottomley C, Riley EM, Mooney JP. Relationship between anaemia, haemolysis, inflammation and haem oxygenase-1 at admission with sepsis: a pilot study. Sci Rep. 2018;8:11198.","journal-title":"Sci Rep"},{"key":"915_CR8","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.3390\/antiox11071300","volume":"11","author":"MG Detsika","year":"2022","unstructured":"Detsika MG, Nikitopoulou I, Veroutis D, Vassiliou AG, Jahaj E, Tsipilis S, et al. Increase of HO-1 expression in critically ill COVID-19 patients is associated with poor prognosis and outcome. Antioxidants (Basel). 2022;11:1300.","journal-title":"Antioxidants (Basel)"},{"key":"915_CR9","unstructured":"Clinical sepctrum of SARS-CoV-2 infection. National Institutes of Health. https:\/\/www.covid19treatmentguidelines.nih.gov\/overview\/clinical-spectrum\/. Accessed 26 Sept 2022."},{"key":"915_CR10","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801\u201310.","journal-title":"JAMA"},{"key":"915_CR11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","volume":"22","author":"JL Vincent","year":"1996","unstructured":"Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707\u201310.","journal-title":"Intensive Care Med"},{"key":"915_CR12","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jmii.2020.03.034","volume":"53","author":"SS Jean","year":"2020","unstructured":"Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect. 2020;53:436\u201343.","journal-title":"J Microbiol Immunol Infect"},{"key":"915_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/thorax.58.5.377","volume":"58","author":"WS Lim","year":"2003","unstructured":"Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377\u201382.","journal-title":"Thorax"},{"key":"915_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"915_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jmii.2020.10.001","volume":"54","author":"WL Su","year":"2021","unstructured":"Su WL, Lin CP, Hang HC, Wu PS, Cheng CF, Chao YC. Desaturation and heme elevation during COVID-19 infection: a potential prognostic factor of heme oxygenase-1. J Microbiol Immunol Infect. 2021;54:113\u20136.","journal-title":"J Microbiol Immunol Infect"},{"key":"915_CR16","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1038\/ni.3590","volume":"17","author":"R Martins","year":"2016","unstructured":"Martins R, Maier J, Gorki AD, Huber KV, Sharif O, Starkl P, et al. Heme drives hemolysis-induced susceptibility to infection via disruption of phagocyte functions. Nat Immunol. 2016;17:1361\u201372.","journal-title":"Nat Immunol"},{"key":"915_CR17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jcrc.2021.09.023","volume":"67","author":"K Kaushal","year":"2022","unstructured":"Kaushal K, Kaur H, Sarma P, Bhattacharyya A, Sharma DJ, Prajapat M, et al. Serum ferritin as a predictive biomarker in COVID-19: a systematic review, meta-analysis and meta-regression analysis. J Crit Care. 2022;67:172\u201381.","journal-title":"J Crit Care"},{"key":"915_CR18","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1001\/jama.1995.03530120060042","volume":"274","author":"C Brun-Buisson","year":"1995","unstructured":"Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults: a multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA. 1995;274:968\u201374.","journal-title":"JAMA"},{"key":"915_CR19","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/all.14657","volume":"76","author":"YD Gao","year":"2021","unstructured":"Gao YD, Ding M, Dong X, Zhang JJ, Kursat Azkur A, Azkur D, et al. Risk factors for severe and critically ill COVID-19 patients: a review. Allergy. 2021;76:428\u201355.","journal-title":"Allergy"},{"key":"915_CR20","doi-asserted-by":"publisher","first-page":"e241","DOI":"10.1017\/S0950268820002368","volume":"148","author":"J Guo","year":"2020","unstructured":"Guo J, Zhou B, Zhu M, Yuan Y, Wang Q, Zhou H, et al. CURB-65 may serve as a useful prognostic marker in COVID-19 patients within Wuhan, China: a retrospective cohort study. Epidemiol Infect. 2020;148:e241.","journal-title":"Epidemiol Infect"},{"key":"915_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1136\/emermed-2020-210081","volume":"39","author":"G Turcato","year":"2022","unstructured":"Turcato G, Zaboli A, Kostic I, Melchioretto B, Ciccariello L, Zaccaria E, et al. Severity of SARS-CoV-2 infection and albumin levels recorded at the first emergency department evaluation: a multicentre retrospective observational study. Emerg Med J. 2022;39:63\u20139.","journal-title":"Emerg Med J"},{"key":"915_CR22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.freeradbiomed.2020.10.016","volume":"161","author":"D Singh","year":"2020","unstructured":"Singh D, Wasan H, Reeta KH. Heme oxygenase-1 modulation: a potential therapeutic target for COVID-19 and associated complications. Free Radic Biol Med. 2020;161:263\u201371.","journal-title":"Free Radic Biol Med"},{"key":"915_CR23","doi-asserted-by":"publisher","first-page":"21462","DOI":"10.1038\/s41598-021-01054-3","volume":"11","author":"DH Kim","year":"2021","unstructured":"Kim DH, Ahn HS, Go HJ, Kim DY, Kim JH, Lee JB, et al. Hemin as a novel candidate for treating COVID-19 via heme oxygenase-1 induction. Sci Rep. 2021;11:21462.","journal-title":"Sci Rep"},{"key":"915_CR24","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1093\/infdis\/jix142","volume":"215","author":"SJ Yoon","year":"2017","unstructured":"Yoon SJ, Kim SJ, Lee SM. Overexpression of HO-1 contributes to sepsis-induced immunosuppression by modulating the Th1\/Th2 balance and regulatory T-cell function. J Infect Dis. 2017;215:1608\u201318.","journal-title":"J Infect Dis"},{"key":"915_CR25","doi-asserted-by":"publisher","first-page":"e23849","DOI":"10.1002\/jcla.23849","volume":"35","author":"IS Tzeng","year":"2021","unstructured":"Tzeng IS. To handle the inflation of odds ratios in a retrospective study with a profile penalized log-likelihood approach. J Clin Lab Anal. 2021;35:e23849.","journal-title":"J Clin Lab Anal"},{"key":"915_CR26","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1007\/s00018-016-2223-0","volume":"73","author":"A Loboda","year":"2016","unstructured":"Loboda A, Damulewicz M, Pyza E, Jozkowicz A, Dulak J. Role of Nrf2\/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism. Cell Mol Life Sci. 2016;73:3221\u201347.","journal-title":"Cell Mol Life Sci"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-022-00915-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-022-00915-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-022-00915-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,4]],"date-time":"2022-12-04T10:02:46Z","timestamp":1670148166000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-022-00915-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,4]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["915"],"URL":"https:\/\/doi.org\/10.1186\/s40001-022-00915-5","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,4]]},"assertion":[{"value":"1 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This single-center, retrospective cohort study was approved by the Institutional Review Board of Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, and New Taipei City, Taiwan, on August 10, 2022 (Protocol No.:11-X-112). This study was conducted in accordance with the guidelines of the amended Declaration of Helsinki. The study protocol was reviewed and an informed consent waiver was obtained from the Institutional Review Board. The application of bio-specimens in this study was reviewed and approved by the Biobank Ethics Committee (Application No: Tzubiobank 2022-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"For this retrospective cohort study, an informed consent waiver was received from the IRB and patient privacy rights were observed regarding any individual data in any form (including individual details, images, or videos).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"275"}}